 |
|
|
|
| |
Submit a Comment on this Paper |
|
|
|
|
| |
 |
|
| |
REAGENTS/MATERIAL:
The following antibodies were used:
rabbit anti-Tom20 (sc-11415),
mouse monoclonal anti-Baf170 (sc-17838),
and goat anti-Opa1 (sc-30572) from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
mouse monoclonal anti-APP (22C11) (MAB348) and
rabbit anti-mitofilin (AB8164) were purchased from Millipore (Temecula, CA, USA);
mouse monoclonal anti-APP (C1/6.1) recognizing the C terminus of APP was kindly provided by P. M. Mathews (Nathan Kline Institute, Orangeburg, NY, USA);
mouse monoclonal anti-APP (G369) raised against 50 amino acids at the C terminus of APP were generously provided by Dr. Sam Gandy (Farber Institute of Neuroscience, Thomas Jefferson University, Philadelphia, PA, USA);
mouse monoclonal anti-N-cadherin (610921),
anti-GM130 (612009),
anti-nicastrin (612290),
anti-Hsp60 (611562),
anti-Tim23 (611223), and
Grim19 (612388) antibodies were purchased from BD Biosciences (Stockholm, Sweden);
rabbit anti-Calnexin (C4731),
anti-actin (A2066),
and anti-Lamp2 (L0668) antibodies were obtained from Sigma Aldrich;
Omi/HtrA2 antibodies (monoclonal)
(polyclonal) were obtained from R&D Systems (Minneapolis, MN, USA);
rabbit anti-PS1-NTF (529591) and
goat polyclonal antibodies recognizing aa 44–63 of human APP (171598; APP-NT) were obtained from Calbiochem EMD Biosciences (San Diego, CA, USA);
mouse monoclonal anti-APP (DE2B4) recognizing Aβ (ab12266) from Abcam (Cambridge, MA, USA).
|
|
|
|
Home
I recommend this paper
